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Abstract
Purpose: Retrospective evaluation of toxicity and results after radiochemotherapy for glioblastoma.
Methods: 46 patients with histopathologically proven glioblastoma received simultaneous radiochemotherapy
(RCT). The mean age at the beginning of therapy was 59 years, the mean Karnofsky performance index 80%. 44
patients had been operated on before radiotherapy, two had not. A total dose of 60 Gy was applied in daily single
fractions of 2.0 Gy within six weeks, 75 mg/m
2/day Temozolomide were given orally during the whole
radiotherapy period.
Results: A local progression could be diagnosed in 34/46 patients (70%). The median survival time amounted to
13.6 months resulting in one-year and two-year survival probabilities of 48% and 8%, respectively.
Radiotherapy could be applied completely in 89% of the patients. Chemotherapy could be completed according
to schedule only in 56.5%, the main reason being blood toxicity (50% of the interruptions). Most of those patients
suffered from leucopenia and/or thrombopenia grade III and IV CTC (Common toxicity criteria). Further reasons
were an unfavourable general health status or a rise of liver enzymes.
The mean duration of thrombopenia and leucopenia amounted to 64 and 20 days. In two patients, blood cell
counts remained abnormal until death. In two patients we noticed a rise of liver enzymes. In one of these in the
healing phase of hepatitis a rise of ASAT and ALAT CTC grade IV was diagnosed. These values normalized after
termination of temozolomide medication. One patient died of pneumonia during therapy.
Conclusion: Our survival data were well within the range taken from the literature. However, we noticed a
considerable frequency and intensity of side effects to bone marrow and liver. These lead to the recommendations
that regular examinations of blood cell count and liver enzymes should be performed during therapy and
temozolomide should not be applied or application should be terminated according to the criteria given by the
manufacturer.
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Background
Since the randomized trial published by Stupp et al. [1]
in 2005 simultaneous radiochemotherapy applying a
t o t a ld o s eo f6 0G yi n3 0f r a c t i o n so f2G ye a c hw i t h i n
six weeks and temozolomide in a dosage of 75 mg/m
2/
day is regarded to be the gold standard in the treatment
of glioblastoma. However, Stupp et al. [1] observed con-
siderable side-effects such as fatigue, bone marrow sup-
pression, opportunistic infections, cerebral hemorrhage,
or liver irritation [1]. They reported a rate of neutrope-
nia and thrombopenia grade III and IV CTC 2.0 (Com-
mon toxicity criteria) of 7%. Other author groups have
published case reports with prolonged pancytopenia and
isolated thrombopenia [2-4]. Additionally, single cases of
liver damage by temozolomide have been reported [5].
During the review of our data we had the impression
that a noticeably higher proportion of our patients suf-
fered from prolonged leucopenia and thrombopenia
than mentioned in the literature. This led us to a more
detailed analysis of our data concerning toxicity of
simultaneous radiochemotherapy for glioblastoma. * Correspondence: marcus.niewald@uks.eu
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From July 2000 to December 2009 a total of 46
patients underwent simultaneous radiochemotherapy
for glioblastoma. Follow-up data were taken into
account until December 2009. The patient characteris-
tics are summarized in Table 1. The mean time
interval between histology and start of radiotherapy
amounted to 27 days.
The patient’s head was fixed by an individual mask,
CT- and MRI-scans (often MPRage and T2 series) were
p e r f o r m e da n df u s e di nt h e3 D - p l a n n i n gs y s t e m .T h e
planning target volume (PTV) was delineated afterwards,
it consisted of the tumour (bed) with a safety margin of
1.5 - 2 cm in all directions respecting anatomical bar-
riers which prevent tumour extension like the scull or
the falx cerebri. Furthermore, critical structures like
brainstem, optic chiasm, optic nerves, lenses and the
inner ear were contoured, the tolerance doses of those
organs were taken into account (dose-volume histo-
gram). A 3D conformal multiple-field technique apply-
ing 6 MV photons of a linear accelerator was used. A
total dose of 60 Gy was applied in single fractions of 2.0
Gy once a day and five times a week using 6 MV
photons of a linear accelerator.
Chemotherapy was applied simultaneously in all
patients. They received 75 mg/m
2 Temozolomide daily
during the whole duration of radiotherapy. In order to
treat nausea and vomiting early, the patients were trea-
ted in an inpatient setting for the first few days of ther-
apy. Laboratory tests (blood cell count, liver enzymes)
were performed once or twice a week, chemotherapy
was interrupted or even terminated in patients showing
white blood cell counts below 3000/μla n d / o rp l a t e l e t
counts below 100.000/μl. Trimethoprim/Sulfamethoxa-
zole were regularly given as a prophylaxis against pneu-
monia caused by Pneumozystis carinii infection.
The first follow-up examination was performed 6-8
weeks after the end of radiotherapy, after that twice a
year, consisting of clinical examination and MRT/CT
scans. Side-effects were graded according to the CTC
3.0 system [6]. Further examinations were performed in
the Department for Neurosurgery. The diagnosis of a
progression was performed according to the RECIST
(response evaluation criteria in solid tumours) criteria.
In order to improve the completeness of data concern-
ing survival, local tumour result, and side effects, struc-
tured questionnaires were sent to the patients’ local
doctors and the local authorities.
All data were entered into a medical databank
(MEDLOG, Fa.Parox, Münster, Germany) and evaluated
statistically. Survival curves were computed using the
Kaplan-Meier estimate, we tried to find out significantly
independent prognostic factors using the Cox regression
hazard model.
All patients had given their written informed consent
before radiochemotherapy. An approval by the local
ethics committee was not necessary due to the retro-
spective nature of this evaluation. The research carried
out here is in compliance with the declaration of
Helsinki.
Table 1 Patient characteristics
Item Mean value/No. of
patients
%
Gender
Male 26 57
Female 20 43
Mean age 58.6 [33.2-73] years
Mean Karnofsky performance index 81% [60-100%]
Localization
frontal 10 22
temporal 26 56
parietal 5 11
occipital 3 7
basal ganglia 1 2
multifocal 1 2
Mean diameter of tumour 4.3 [1.5-8.0] cm
Size of edema
none 5 11
< 1 cm 6 13
> 1 cm 15 33
half hemisphere 18 39
total hemisphere 2 4
Pre-treatment
complete resection 27 59
subtotal resection 5 11
partial resection 12 26
biopsy 2 4
Corticoid intake (beginning of
therapy)
None 0 0
< 5 mg/day 1 2
< 10 mg/day 14 30
< 20 mg/day 21 46
< 30 mg/day 2 4
> 30 mg/day 8 18
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Median overall survival amounted to 13.6 months, with
one/two year survival rates of 48 and 8%, respectively.
T h ed a t aa r ed e p i c t e di nF i g u r e1 .L o c a lt u m o u rp r o -
gression was seen in 32 patients (82%) resulting in a 6/
12 months local control probability of 59.4 and 30%,
respectively. In multivariate analysis, the total dose (p =
0.0035) and the age (p = 0.0445) were found to be sig-
nificant prognostic factors whereas pre-treatment, dose
of cortisone, change of thed o s eo fc o r t i s o n ed u r i n g
therapy, latency between surgery and radiotherapy, and
Karnofsky performance status were not. The results can
also be illustrated in terms of median survival: the med-
ian survival of older patients amounted to 0.88 years (n
= 23; > = 59 years) whereas the survival of younger
patients was 1.07 years (n = 23, < 59 years). Patients
having been treated completely showed a median survi-
val of 1.05 years (n = 41) whereas patients with an
incomplete treatment only survived 0.81 years in median
(differences not significant using Mantel-Haensel-test).
The planned total dose of 60 Gy could be applied to
41 (89%) patients. In the remaining five, therapy had to
be terminated prematurely after reaching doses of 38 Gy
(1 pat.), 40 Gy (1 pat.), 56 Gy (2 pats.) and 58 Gy (1
pat.) due to a deterioration of general health status.
The dose of corticosteroids (all patients were applied
dexamethasone) needed by the patients was evaluated
after radiochemotherapy and compared to the doses
taken before. The dexamethasone dosage was chosen
regularly according to the patient’s complaints and the
general health status. Due to an often very fast dete-
rioration of the patients’ status CT- and MRI examina-
tions were not performed always. Thus, we cannot
exclude that in some patients a local tumor progression
may have lead to termination of therapy. In 63% of the
patients corticoid intake could be reduced by at least
one step (compare Table 1), in a further 21% the dose
remained constant, and in the remaining 16% the dose
had to be increased.
Chemotherapy could be applied completely in 26
(56.5%) patients. Two of these patients had a short (< 7
days) interruption of medication, one due to a subcuta-
neous liquor cushion which had to be treated surgically,
the other due to an episode of seizures. The mean dura-
tion of continuous temozolomide intake was 35 (6-49)
days. On the other hand, chemotherapy could not be
given completely in 20 patients (43%), due to a dete-
rioration of blood cell count, worsening of general
health status and liver damage. One patient died of
pneumonia during a phase of bone marrow aplasia hav-
ing received a radiotherapy dose of 38 Gy.
The blood cell counts before and after radioche-
motherapy as well as the minimal values during radio-
therapy are summarized in Table 2. As stated above,
the side effects were classified according to the CTC
3.0 system, resulting in the distributions depicted in
F i g u r e s2a n d3 .I ns u m m a r y ,t o x i c i t yg r a d et h r e eC T C
to platelet count was diagnosed in two patients (4%)
and grade 4 in six patients (13%), in total, six males
and 2 females, whereas toxicity grade 4 CTC to white
blood cell count was found in seven patients (15%,
four males and three females) as the most unfavour-
able values during therapy. However, at the end of
radiotherapy there were still three patients (7%) with
grade 3 and five patients (11%) with grade 4 toxicity to
the platelet count whereas only 4 patients (9%) were
diagnosed to have toxicity to the leucocyte count grade
4 CTC. The duration of these side effects is summar-
ized in Table 3.
Nine patients (20%) were applied erythrocyte transfu-
sions due to symptomatic anemia (2-6 units), in six of
those patients further thrombocyte transfusions were
Figure 1 Overall survival (Kaplan-Meier estimate, survival curve solid, borders of 95% interval dashed).
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leucopenia for on average 10 days [2-20 days].
F r e q u e n c ya n dg r a d eo ft o x i c i t yt ot h el i v e ra r es u m -
marized in Table 4. In one patient, GOT, GPT and g-
GT values were elevated extremely up to values of 3172
U/l, 9020 U/l and 782 U/l, respectively. These values
recovered at least in part after the end of chemotherapy.
This patient was in the recovery phase of a hepatitis B
infection, which was not known at the beginning of
therapy. Chemotherapy was terminated due to liver toxi-
city in two patients.
Two (4%) of the patients had adjuvant chemotherapy
using temozolomide after radiochemotherapy. This
results from the fact that adjuvant chemotherapy was
not applied routinely in the department at that time the
patients were treated (partially before Stupp had pub-
lished his trial [1]). Three patients (7%) underwent
further surgery due to local relapse.
Discussion
In the treatment of glioblastoma the effect of the combi-
nation of standard radiotherapy with simultaneous che-
motherapy using temozolomide has been examined for
at least 15 years. The first phase II trials were published
in 1993 and 1996 [7,8]. Brock et al. [9] recommended a
dosage of 75 mg/m
2/day which is still regarded to be
the standard. Very favourable survival data after radio-
chemotherapy were found by Stupp et al. in 2002 [10]
(2-year-survival rate 31%). In the randomized trial pub-
lished by the same author group in 2005 [1] the results
of radiotherapy alone applying a total dose of 60 Gy in
30 fractions within six weeks were compared with the
same radiotherapy plus a chemotherapy of 75 mg/m
2/
day temozolomide given simultaneously. The latter
patients also received adjuvant chemotherapy with six
courses of temozolomide (150-200 mg/m
2). The combi-
nation therapy clearly improved survival (median survi-
val 14.6 vs. 12.1 months, one-year survival rate 61.1% vs.
50.6%); since that time radiochemotherapy is regarded
to be the gold standard in the treatment of glioblastoma.
A second randomized trial with fewer patients was pub-
lished by Athanassiou in 2005 [11]. The authors stated a
median survival time of 8.9 months (radiotherapy) com-
pared to 13.6 months (radiochemotherapy) resulting in
a one-year survival probability of 15.7% vs. 56.3%.
In our collective, radiochemotherapy was terminated
prematurely in 43% of the patients. This value seems
high compared to those reported in the two randomized
trials mentioned above: Stupp et al. [1] cite an early dis-
continuation of Temozolomide application in 13% of the
patients, the main reason was side effects. Hematotoxi-
city grade 3 and 4 were noticed in 7% of the patients,
mainly neutropenia and thrombopenia.
Athanassiou et al. [11] found a myelosuppression in
8.7% of their patients. Leucopenia grade 3 and 4 were
noticed in 3.5% and thrombopenia grade 3 and 4 in
5.2%. One patient with severe myelotoxicity died of sep-
sis. Unfortunately, the authors did not state in how
many patients treatment could be applied completely or
how long the duration of side effects was.
Furthermore, we have found several papers showing
retrospective toxicity data in the literature, see Table 5.
In summary, the authors stated a rate of leucocyte toxi-
city grades 3 and 4 CTC in the range 3% to 15% and a
Table 2 Mean blood values
Before therapy Nadir (minimal values during therapy) After therapy
Hemoglobine [g/dl] 13.3 [10.4-16.7] 12.0 [7.1-15.3] 12.9 [7.1-15.3]
Leucocytes [1000/μl] 10.6 [2.2-20.5] 5.3 [0.1-11.0] 6.2 [0.2-14]
Thrombocytes [1000/μl] 227 [103-390] 141 [4-291] 166 [14-419]
Figure 2 CTC-Classification of hematologic toxicity (maximum).
Figure 3 CTC-Classification of hematologic toxicity (end of
therapy).
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the range 0 - 15% of their patients [12-20]. These results
have been analyzed in detail, the known prognostic fac-
tors (elderly patients, unfavourable Karnofsky perfor-
mance index, the percentage of patients having been
operated on) did not influence markedly the rate of side
effects.
Some interesting case reports were also found. Nagane
et al. [3], Jalali et al. [2] and Singhal et al. [4] report a
total of 4 cases with long-lasting myelosuppression after
temozolomide (one patient has died of sepsis).
Liver toxicity is currently under debate. While New-
lands et al. [21] could not find a liver metabolism of
temozolomide, liver affections were reported in litera-
ture [5,22,23]. In one case, temozolomide was applied
together with valproic acid, in the two other cases a
viral hepatitis was reactivated. We have seen two
patients with liver toxicity which led to interruption of
chemotherapy, reactivation of hepatitis could be proven
in one.
Due to the low number of events prognostic factors
could not be computed in our collective. Data taken
from the literature show that female patients may have
a higher risk of hematologic toxicity than males [24].
Armstrong et al. [25] state after having analyzed an
ample collective of 680 patients that in males a body
surface > 2 m
2, missing medication with steroids, and
bowel medication may enhance the risk of high-grade
toxicity, while in females a creatinine level > 1 mg/dl, a
platelet count below 270000/mm
3, missing medication
Table 3 Duration of side effects (days)
3° CTC 4° CTC
Thrombocytes (n = 6) 64 [26-125] 24 [14-38]
Leucocytes (n = 7) 20 [5-28] 13 [2-22]
Hemoglobine (n = 1) 4 0
Table 4 Liver toxicity at the beginning and end of
therapy and maximum values
3° CTC 4°CTC
Start Maximum End Start Maximum End
g-GT 1 3 4 0 0 0
GOT 0 1 0 0 1 0
GPT 0 4 3 0 1 0
Table 5 Literature data
Authors Number of
patients
Toxicity 3/4°
leucocytes
Toxicity 3/4°
thrombocytes
Remarks I Remarks II
Randomized trials
Athanassiou et al.
2005 [11]
130 3.5% 5.2% 1 pat. died of sepsis
Stupp et al., 2005
[1]
573 4% 3% Severe infections in 3%
Retrospective analyses
Armstrong 2008
[12]
203 Clinically significant lymphopenia
in 45% of women and 6% of
men
Abstract
Combs et al. 2005
[26]
53 2% 0 No severe late effects temozolomide 50 mg/m
2
Combs et al. 2008
[14]
160 Hematologic toxicity
5% (50 mg/m
2) vs. 14% (75 mg/
m
2)
Premature discontinuation
6.5% vs. 14%
Comparison temozolomide 50 vs. 75 mg/m
2
Fiorica et al. 2010
[15]
42 0 5%
Gerber 2007 [16] 52 Neutro-penia
In 18%
15% Mean duration 332 days
[1-389 days]
10% required platelet transfusions, 67%
discontinued radiochemo-therapy
Gerstein et al.
2009 [17]
51 Hematologic toxicity
14%
Premature discontinuation
in 41%
Jeon 2009 [27] 79 Hematologic toxicity
7.5%
1 pat. with severe lung
infection
Kimple 2010 [19] 32 3% 0
Minniti et al. 2008
[20]
32 3% 3% Pneumonia in 3%
Our data 46 15% 17% 43% discontinued treatment
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analgesics are independent prognostic factors.
Our data do not allow to give clear reasons for the
discrepancies between our results and those taken from
the literature. We only can assume that one reason may
be the retrospective evaluation of an unselected patient
collective performed here with a wide variety of ages,
Karnofsky performance statuses and tumour extensions
as well as co-morbidity. Otherwise, it may be possible
that under the impression of the first long-lasting hae-
matological side effects medication was interrupted even
earlier than recommended by the manufacturer which
may have lead to a virtual higher proportion of unfa-
vourable results.
T oo u ro p i n i o nt h eo n l ys t r a t e g yt ol i m i tt h i st o x i c i t y
is to strictly follow the rules given by the manufacturer
and to interrupt or to terminate the medication at the
time points recommended. To our experience it would
not have been possible to identify those patients with an
unfavourable result before radiotherapy, thus alteration
of the fractionation protocol, reduction of the dose of
temozolomide prematurely or even not to apply temozo-
lomide concomitantly to radiotherapy do not appear to
be reasonable possibilities.
Conclusions
Our values fit well to those taken from the retrospective
analyses. However, the results in the randomized trials
are far more favourable which may be a result of patient
selection. Unfortunately, the known prognostic factors
could not be tested in our collective.
Bearing in mind the limited power of a retrospective
evaluation we would like to conclude that simultaneous
radiochemotherapy for glioblastoma yields reasonable
local control and survival rates. However, a certain risk
of toxicity to the bone marrow must be taken into
account.
According to the recommendations given by the man-
ufacturer should be interrupted if neutrophile count is
between 0.5 - 1.5 × 10
9/l or thrombocyte count is
between 10 and 100 × 10
9/l or non-hematologic toxicity
reaches CTC grade 2. Below these blood cell counts or
in case of non-hematologic toxicity CTC grades 3 and 4
medication should be terminated.
List of abbreviations
CTC: Common toxicity criteria [6].
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